MNPR Insider Trading
Insider Ownership Percentage: 20.50%
Insider Buying (Last 12 Months): $62,081.20
Insider Selling (Last 12 Months): $1,166,690.00
Monopar Therapeutics Share Price & Price History
Current Price: $33.82
Price Change: ▼ Price Decrease of -0.83 (-2.40%)
As of 06/12/2025 05:00 PM ET
Monopar Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2025 | Tactic Pharma Llc | Major Shareholder | Sell | 33,334 | $35.00 | $1,166,690.00 | 822,255 |  |
| 10/28/2024 | Karthik Radhakrishnan | CFO | Buy | 1,550 | $16.25 | $25,187.50 | 1,550 | |
| 6/20/2024 | Andrew Cittadine | COO | Buy | 4,101 | $3.70 | $15,173.70 | 37,226 | |
| 6/17/2024 | Andrew Cittadine | COO | Buy | 2,400 | $4.50 | $10,800.00 | 30,724 | |
| 6/13/2024 | Andrew Cittadine | COO | Buy | 2,400 | $4.55 | $10,920.00 | 25,924 | |
| 6/3/2024 | Andrew Cittadine | COO | Buy | 2,400 | $3.80 | $9,120.00 | 21,124 | |
| 5/31/2024 | Andrew Cittadine | COO | Buy | 2,400 | $3.20 | $7,680.00 | 18,724 | |
| 5/29/2024 | Andrew Cittadine | COO | Buy | 2,400 | $3.20 | $7,680.00 | 13,924 | |
| 11/14/2022 | Andrew Cittadine | COO | Buy | 1,210 | $15.00 | $18,150.00 | 2,847 | |
Monopar Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/19/2025 | Jane Street Group LLC | 10,357 | $0.38M | 0.0% | N/A | 0.169% |  |
| 5/16/2025 | Goldman Sachs Group Inc. | 18,480 | $0.67M | 0.0% | N/A | 0.302% | |
| 5/16/2025 | ADAR1 Capital Management LLC | 100,774 | $3.67M | 0.7% | -22.5% | 1.648% | |
| 5/15/2025 | OMERS ADMINISTRATION Corp | 9,000 | $0.33M | 0.0% | N/A | 0.147% | |
| 5/14/2025 | Affinity Asset Advisors LLC | 62,000 | $2.26M | 0.2% | N/A | 1.014% | |
| 5/14/2025 | AlphaQuest LLC | 1,215 | $44K | 0.0% | N/A | 0.020% | |
| 4/23/2025 | Gerber LLC | 5,601 | $0.20M | 0.2% | N/A | 0.092% | |
| 2/17/2025 | Point72 Asset Management L.P. | 167,892 | $3.69M | 0.0% | N/A | 2.752% | |
| 2/17/2025 | Janus Henderson Group PLC | 1,046,899 | $23.44M | 0.0% | N/A | 17.162% | |
| 2/14/2025 | RA Capital Management L.P. | 511,207 | $11.25M | 0.1% | N/A | 8.380% | |
| 2/14/2025 | Adage Capital Partners GP L.L.C. | 599,195 | $13.18M | 0.0% | N/A | 9.823% | |
| 2/13/2025 | ADAR1 Capital Management LLC | 130,037 | $2.86M | 0.6% | N/A | 2.132% | |
| 2/12/2025 | Geode Capital Management LLC | 38,596 | $0.85M | 0.0% | +174.4% | 0.633% | |
| 2/12/2025 | JPMorgan Chase & Co. | 2,037 | $45K | 0.0% | N/A | 0.033% | |
| 10/31/2023 | Windsor Advisory Group LLC | 89,974 | $56K | 0.1% | N/A | 0.635% | |
| 8/13/2021 | Geode Capital Management LLC | 28,761 | $0.17M | 0.0% | +9.0% | 0.229% | |
| 8/13/2021 | Vanguard Group Inc. | 97,462 | $0.57M | 0.0% | +116.2% | 0.775% | |
| 5/21/2021 | Citadel Advisors LLC | 12,479 | $77K | 0.0% | N/A | 0.099% | |
| 5/18/2021 | Citadel Advisors LLC | 12,479 | $77K | 0.0% | N/A | 0.099% | |
| 5/17/2021 | Royal Bank of Canada | 9,130 | $57K | 0.0% | N/A | 0.073% | |
| 5/12/2021 | Northern Trust Corp | 36,001 | $0.22M | 0.0% | -38.8% | 0.286% | |
| 5/12/2021 | Geode Capital Management LLC | 26,394 | $0.16M | 0.0% | N/A | 0.210% | |
| 5/7/2021 | BlackRock Inc. | 11,229 | $70K | 0.0% | +108.3% | 0.089% | |
Data available starting January 2016
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More on Monopar Therapeutics
Today's Range
Now: $33.82
52 Week Range
Now: $33.82
Volume
43,269 shs
Average Volume
37,860 shs
Market Capitalization
$206.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
Who are the company insiders with the largest holdings of Monopar Therapeutics?
Who are the major institutional investors of Monopar Therapeutics?
Which major investors are selling Monopar Therapeutics stock?
In the previous quarter, MNPR stock was sold by these institutional investors:
- ADAR1 Capital Management LLC
Which major investors are buying Monopar Therapeutics stock?
In the previous quarter, MNPR stock was bought by institutional investors including:
- Affinity Asset Advisors LLC
- Goldman Sachs Group Inc.
- Jane Street Group LLC
- OMERS ADMINISTRATION Corp
- Gerber LLC
- AlphaQuest LLC
During the last year, these company insiders have bought Monopar Therapeutics stock:
- Tactic Pharma Llc (Major Shareholder)
- Andrew Cittadine (COO)
Learn More investors buying Monopar Therapeutics stock.
